Creative Medical Technology HoldingsCELZ -4.92%34 Net Current Asset Value is $1.55 as of Mar. 2026, which is 118% above its 10-year median of 0.71. GuruFocus rates CELZ with a GF Score™ of 34/100 and a GF Value™ of $0.32 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 943 Biotechnology companies, Creative Medical Technology Holdings ranks better than 95.97% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for Creative Medical Technology Holdings's Net Current Asset Value or its related term are showing as below:
CELZ'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.29 Med: 0.71 Max: 2.87
Current: 0.61
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Creative Medical Technology Holdings was 2.87. The lowest was 0.29. And the median was 0.71.
CELZ's Price-to-Net-Current-Asset-Value is ranked better than 95.97% of 943
companies
in the Biotechnology industry
Industry Median: 4.91
vs CELZ: 0.61
Creative Medical Technology Holdings (NAS:CELZ) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Creative Medical Technology Holdings Net Current Asset Value Related Terms
Creative Medical Technology Holdings Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Medical Technology Holdings Net Current Asset Value Chart
CELZ vs FBLG, GLMD, ALZN: Net Current Asset Value Comparison
For the Biotechnology subindustry, Creative Medical Technology Holdings's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creative Medical Technology Holdings Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Creative Medical Technology Holdings's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Creative Medical Technology Holdings's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $1.55 mean?
Creative Medical Technology Holdings (CELZ) has a Net Current Asset Value of $1.55 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Creative Medical Technology Holdings and its competitors. This is 118% above median its historical median of 0.71. Over the past decade, Creative Medical Technology Holdings' Net Current Asset Value has ranged from 0.29 to 2.87. According to the industry distribution chart, Creative Medical Technology Holdings ranks #38 out of 943 companies in the Biotechnology industry, placing it in the top 4%.
Is Creative Medical Technology Holdings' Net Current Asset Value too high?
Creative Medical Technology Holdings' current Net Current Asset Value of $1.55 is 118% above median its 10-year median of 0.71. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 2.87. The Biotechnology industry median Net Current Asset Value is 4.91. Creative Medical Technology Holdings' value of $1.55 is 68.4% below this industry median. Based on the distribution chart, Creative Medical Technology Holdings ranks #38 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Creative Medical Technology Holdings has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' Net Current Asset Value compare to FBLG and GLMD?
According to the Biotechnology industry distribution chart, Creative Medical Technology Holdings ranks #38 out of 943 companies for Net Current Asset Value. This places Creative Medical Technology Holdings in the top 4% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.91. Creative Medical Technology Holdings' value of $1.55 is 68.4% below this benchmark. Historically, Creative Medical Technology Holdings' own Net Current Asset Value has ranged from 0.29 to 2.87 over the past decade. While the company's 10-year median is 0.71 vs. the industry median of 4.91, Creative Medical Technology Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.91, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creative Medical Technology Holdings's current Net Current Asset Value of $1.55 is 68.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Creative Medical Technology Holdings and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creative Medical Technology Holdings's current Net Current Asset Value is $1.55, which is 118% above median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $0.94 — trading 194.2% above its estimated fair value. The current Net Current Asset Value is $1.55, which is 118% above median its 10-year median of 0.71 and 68.4% below the Biotechnology industry median of 4.91. Creative Medical Technology Holdings' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current Net Current Asset Value is $1.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?
Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued.
The current stock price of $0.94 is trading 194.2% above its estimated GF Value™ of $0.32.
GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.
Key valuation signals for CELZ:
Net Current Asset Value: $1.55 (118% above median its 10-year median of 0.71)
GF Value™: $0.32 vs. price of $0.94 (194.2% above fair value)
Industry Position: 68.4% below the Biotechnology median (#38 of 943)
No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creative Medical Technology Holdings Business Description
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
34GF Score
Get the complete analysis for CELZ
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CELZ has been successfully added to your 
